Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.4K Hold
85
0.01% 67
2026
Q1
$15.6K Hold
85
0.01% 68
2025
Q4
$15K Hold
85
0.01% 65
2025
Q3
$11.9K Hold
85
0.01% 61
2025
Q2
$10.7K Sell
85
-22
-21% -$2.74K 0.01% 64
2025
Q1
$14.6K Buy
107
+85
+386% +$12.2K 0.01% 61
2024
Q4
$3.36K Sell
22
-26
-54% -$4.38K ﹤0.01% 65
2024
Q3
$9.3K Sell
48
-52
-52% -$10.9K ﹤0.01% 66
2024
Q2
$23.2K Hold
100
0.01% 65
2024
Q1
$21.5K Sell
100
-121
-55% -$28.3K 0.01% 90
2023
Q4
$57.2K Sell
221
-511
-70% -$126K 0.03% 67
2023
Q3
$188K Sell
732
-102
-12% -$27.3K 0.1% 55
2023
Q2
$238K Sell
834
-27
-3% -$8.04K 0.1% 62
2023
Q1
$239K Buy
+861
New +$238K 0.15% 54

Other funds holding BIIB

Brown Shipley & Co's BIIB Position: Q2 2026 in Review

Brown Shipley & Co held its Biogen (BIIB) position steady in Q2 2026 at 85 shares worth $18.4K. The position accounts for 0.01% of the portfolio, ranked #67.

Brown Shipley & Co first reported a position in BIIB in Q1 2023 and has held it in 14 quarters since. The position peaked at $239K in Q1 2023. 405 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Brown Shipley & Co held 85 shares of Biogen worth $18.4K as of Q2 2026.
  • Brown Shipley & Co left its Biogen share count unchanged in Q2 2026.
  • Biogen made up 0.01% of Brown Shipley & Co's portfolio in Q2 2026, its #67 holding.
  • Brown Shipley & Co first reported a position in Biogen in Q1 2023 and has held it in 14 quarters since.
  • Brown Shipley & Co's Biogen position peaked at $239K in Q1 2023.
  • 405 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Brown Shipley & Co's 13F filing for Q2 2026, filed 14 Jul 2026.